MedPath

Effects for glucose metabolism, body composition, and circulatory dynamics of SGLT2 inhibitor

Not Applicable
Conditions
Type 2 diabetes mellitus
Registration Number
JPRN-UMIN000017195
Lead Sponsor
Division of Neurology, Respirology, Endocrinology and Metabolism, Department of Internal Medicine, Faculty of Medicine, University of Miyazaki
Brief Summary

Not available

Detailed Description

Not available

Recruitment & Eligibility

Status
Complete: follow-up complete
Sex
All
Target Recruitment
30
Inclusion Criteria

Not provided

Exclusion Criteria

1. The patients with severe macroangiopathy 2. The patients with severe renal and/or liver dysfunction. 3. Women who were pregnant, lactating, or capable of pregnancy

Study & Design

Study Type
Interventional
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
The changes of glucose metabolism, incretin secretion, gut peptides secretion, body weight, body composition, and basal metabolic rate.
Secondary Outcome Measures
NameTimeMethod
© Copyright 2025. All Rights Reserved by MedPath